[Ip-health] Scaling production of vaccines and therapeutics. What can be done, what went wrong.

James Love james.love at keionline.org
Tue Dec 15 05:50:38 PST 2020


Legislators in the US, Germany, the UK, and some other countries that
played a role in the funding/development of useful products for COVID
should ask governments about the measures that would expand the production
capacity for vaccines and therapeutics, since Pfizer, Moderna, AstaZeneca,
Regeneron or Lilly seem to be pretty far behind demand.

WHO members should also be asking what it has done in this regard.

In all cases, emphasis should be on the benefits of sharing know-how,
rights in data and inventions, and access to biological resources.

If policy makers think it's too late now, then at a minimum, they should be
asked to provide some explanation as to what went wrong, earlier on, that
leaves us in a position of a slower than necessary manufacturing roll-out,
and larger than necessary global disparity of access.

It's not as if governments did not have the mechanisms or leverage to have
forced sharing of know-how, rights in data and inventions, and access to
biological resources.

Jamie

-- 
James Love.  Knowledge Ecology International
U.S. Mobile +1.202.361.3040
U.S. office phone +1.202.332.2670
http://www.keionline.org <http://www.keionline.org/donate.html>
twitter.com/jamie_love


More information about the Ip-health mailing list